Researchers at Peter Mac have uncovered potential new heredity genes that might be responsible for causing one of the most ...

Serous ovarian tumors of low malignant potential (SLMP)--also called borderline tumors of the ovary--represent a heterogeneous group of ovarian epithelial neoplasms. In general, this tumor type ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer. In the cancer world — or anywhere — the ability to ...

Ovarian cancer, often called the silent killer, presents one of the most serious health threats women face globally. Its ...

Avutometinib and defactinib target KRAS-mutated recurrent low-grade serous ovarian cancer, potentially becoming the first FDA-approved treatment for this specific cancer type. The NDA is supported by ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

FIGO Stage: A classification system used to describe the extent of cancer spread, developed by the International Federation of Gynecology and Obstetrics. Low-Grade Serous Carcinoma (LGSC): A type ...